METAMIZOL METABOLITES ANTINOCICEPTION IN RATS
7
model after administration of MET will be related to Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF,
Brune K. 2007. Dipyrone elicits substantial inhibition of periph-
eral cyclooxygenases in humans: new insights into the pharmacol-
ogy of an old analgesic. FASEB J 21:2343–2351.
the pharmacokinetics of both metabolites, MAA and
AA [Hinz et al., 2007].
Kis B, Snipes JA, Busija DW. 2005. Acetaminophen and the
cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertain-
ties. J Pharmacol Exp Ther 315:1–7.
ACKNOWLEDGMENTS
The authors would like to thank Mr. Luis Oliva Levy M, Zylber-Katz E, Rosenkranz B. 1995. Clinical pharmacoki-
netics of dipyrone and its metabolites. Clin Pharmacokinet
and Mr. Froylan Sánchez for technical assistance.
2
8:216–234.
López-Muñoz FJ. 1994. Surface of synergistic interaction between
dipyrone and morphine in the PIFIR model. Drug Dev Res
REFERENCES
3
3:26–32.
Aronoff DM, Oates JA, Boutaud O. 2006. New insights into the
mechanism of action of acetaminophen: Its clinical pharmacologic
López-Muñoz FJ, Godínez-Chaparro B, Huerta-Cruz JC, Guevara-
López U, Domínguez-Ramírez AM, Cortés-Arroyo AR. 2008. The
antinociceptive efficacy of morphine, metamizol, or their combi-
nation in an experimental rat model with different level of inflam-
matory pain. Pharmacol Biochem Behav 9:196–201.
characteristics reflect its inhibition of two prostaglandin H
thases. Clin Pharmacol Ther 70:9–19.
2
syn-
Brogden RN. 1986. Pyrazolone derivatives. Drugs 32:60–70.
Brune K, Alpermann H. 1983. Non-acidic pyrazolones: inhibition of
prostaglandin production, carrageenan oedema and yeast fever.
Agents Actions 13:360–363.
López-Muñoz FJ, Salazar LA, Castañeda-Hernández G, Villarreal
JE. 1993. A new model to assess analgesic activity: pain-induced
functional impairment in the rat (PIFIR). Drug Dev Res 28:169–
1
75.
Campos C, de Gregorio R, García-Nieto R, Gago F, Ortiz P,
Alemany S. 1999. Regulation of cyclooxygenase activity by
metamizol. Eur J Pharmacol 378:339–347.
Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Licht-
man HA, Cascio GM, Bisogno T, Di Marzo V, Nüsing R, et al.
2
012. Novel bioactive metabolites of dipyrone (metamizol). Bioorg
Carlsson RH, Helmreich J, Jurna I. 1986. Activation of inhibition
from the periaqueductal grey matter mediates central and analge-
sic effect of metamizol (dipyrone). Pain 27:373–390.
Med Chem 20:101–107.
Rowland López M, Tozer TN. 2010. Clinical pharmacokinetics and
pharmacodynamics: concepts and applications, 4th edn. Philadel-
phia: Lippincott Williams & Wilkins.
Chandrasekharan NV, Dai H, Turepus Roos KL, Evanson NK,
Tomsik J, Elton TS. 2002. COX-3, a cyclooxygenase-1 variant
inhibited by paracetamol and other analgesic/antipyretic drugs:
cloning, structure and expression. Proc Nat Acad Sci U S A
Tatsuo MA, Carvalho WM, Silva CV, Miranda AE, Ferreira SH,
Francischi JN. 1994. Analgesic and anti-inflammatory effects of
dipyrone in rat adjuvant arthritis model. Inflammation 18:399–
99:13926–13931.
4
05.
Domínguez AM, Hernández GP, Ventura R, Díaz MI, López-
Muñoz FJ. 2000. Analgesic efficacy of the combination
metamizol+morphine after subchronic treatment in rats. Drug
Dev Res 51:260–267.
Teng Y, Zhang H, Liu R. 2011. Molecular interaction between
4-aminoantipyrine and catalase reveals a potentially toxic mecha-
nism of the drug. Mo BioSyst 7:3157–3163.
Domínguez-Ramírez AM, Cortés-Arroyo AR, Hurtado y de la Peña
M, Medina LJR, López-Muñoz FJ. 2010. Effect of metamizol on
morphine pharmacokinetics and pharmacodynamics after acute
and subchronic administration in arthritic rats. Eur J Pharmacol
Tortorici V, Vásquez E, Vanegas H. 1996. Naloxone partial reversal
of the antinociception produced by dipyrone microinjected into
the periaqueductal gray of rats: possible involvement of medullary
off- and on-cells. Brain Res 725:106–110.
6
4:94–101.
Vanegas H, Tortorici V. 2002. Opioidergic effects of nonopioid
analgesics on the central nervous system. Cell Mol Neurobiol
22:655–661.
Duarte ID, Dos Santos IR, Lorenzetti B, Ferreira SH. 1992.
Analgesia by direct antagonism of nociceptor sensitization involves
the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 217:
Ventura R, Díaz MI, Déciga M, Terrón JA, Domínguez AM, López-
Muñoz FJ. 2002. Involvement of peripheral cyclooxygenase-1 and
cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol
54:405–412.
2
25–227.
EMEA. 2003. Metamizole. Summary report. Committee for veteri-
nary medicinal products. Evaluation Unit. European Agency for
the Evaluation of Medicinal Products.
Ventura R, Díaz MI, Hernández P, Domínguez AM, Salazar LA,
Cabré F, López-Muñoz FJ. 2000. Role of COX-1 and COX-2-
synthesized prostaglandins in a rat model of arthritic pain. Drug
Dev Res 51:253–259.
Fieser LF, Jones JE. 1955. N-methylformanilide. In: Horning EC,
editor. Organic Syntheses Collective. Volume III. New York:
Wiley & Sons Inc. p 590–591.
Guide for Care and Use of Laboratory Animals. 2011. 8th edn.
Washington, DC: National Academic Press.
Weithmann KU, Alpermann HG. 1985. Biochemical and Pharmaco-
logical effects of dipyrone and its metabolites in model systems
related to arachidonic cascade. Arzneim Forsh/ Drug Res 35:947–
Hernández-Delgadillo GP, Ventura R, Díaz MI, Domínguez AM,
López-Muñoz FJ. 2002. Metamizol potentiates morphine anti-
nociception but not constipation after chronic treatment. Eur J
Pharmacol 441:177–183.
9
52.
Yoshioka S, Ogata H. 1977. Stability of sulpyrine II. Hydrolysis in
acid solution. Chem Pharm Bull 25:484–490.
Drug Dev. Res.